In the medical device industry, there exists a strict evidence-based dividing line between "claiming efficacy" and "proving efficacy with credible data". For hydrogen-oxygen generators, how has Asclepius Meditec built a quantifiable, verifiable evidence framework through National Natural Science Foundation of China (NSFC) projects, multicenter clinical trials and real-world studies?

This article systematically demonstrates the scientific rigor of Asclepius Meditec’s R&D system from three dimensions: research funding support, clinical trial design and academic publications. It is intended for medical practitioners, scientific researchers and consumers who value scientific evidence.

National Natural Science Foundation: Official Research Qualification for Hydrogen-Oxygen Medical Studies

The National Natural Science Foundation of China (NSFC) represents the top-tier national research funding program for fundamental research in China. Receiving NSFC funding means the research proposal has passed rigorous peer review by national academic experts.

According to publicly accessible grant data on the NSFC official website, multiple research projects associated with Asclepius Meditec have obtained financial support. Representative projects are listed below:

In addition, a project initiated in 2020 titled "Protective Effect of Hydrogen Inhalation on Sepsis-Induced Acute Lung Injury and Its Mitochondrial Quality Control Mechanism" (Grant No. 82070089) was undertaken by Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, with a total funding of RMB 550,000.

Clinical Trial Registration: Upgraded Evidence Grade from Single-Center Observations to Multicenter RCTs

Clinical trial registration serves as the gold standard to validate the efficacy of medical products. Searching "hydrogen-oxygen" or "Asclepius" on the Chinese Clinical Trial Registry (ChiCTR, www.chictr.org.cn, a primary registry of the WHO International Clinical Trials Registry Platform) retrieves the following registered studies (Source: ChiCTR public database):

The trial ChiCTR2300070422 is led by the First Affiliated Hospital of Guangzhou Medical University, in collaboration with Zhongshan Hospital Fudan University, the First Hospital of Hebei Medical University and other institutions. The first participant was enrolled on April 11, 2023, and Shanghai Asclepius Meditec Co., Ltd. is clearly marked as the trial funding source.

On the international academic stage, a landmark multicenter randomized controlled trial co-conducted by Asclepius Meditec and Academician Zhong Nanshan’s team was published in Respiratory Research on May 13, 2021, titled Hydrogen/oxygen therapy for the treatment of an acute exacerbation of chronic obstructive pulmonary disease.

The study explicitly concluded that mixed hydrogen-oxygen inhalation therapy achieved superior relief of dyspnea, cough and expectoration compared with pure oxygen therapy among AECOPD patients, with favorable safety and tolerability profiles (Source: Respiratory Research, 2021). In the same year, a prospective real-world follow-up research published in Medical Gas Research tracked 82 stage III and IV cancer patients. The results demonstrated significant improvements in fatigue, insomnia, poor appetite and pain after inhalation of a hydrogen-oxygen mixture (66.6% hydrogen, 33.3% oxygen).

Academic Paper Publications: Quantifiable Scientific Output

A total of 107 SCI papers related to Asclepius Meditec have been published (Source: PubMed database search keyword: Shanghai Asclepius Meditech), covering a wide range of indications including respiratory diseases, neurological disorders, cardiovascular diseases and adjuvant tumor treatment.

A case report published in OncoTargets and Therapy in 2019 documented a 44-year-old female patient with brain metastasis from non-small cell lung cancer who failed conventional therapies. After daily inhalation of hydrogen-oxygen mixture (66.6% hydrogen, 33.3%), multiple brain tumors shrank markedly within 4 months and completely vanished after 1 year. This marks the first documented case of remarkable tumor response to hydrogen monotherapy.

Though single-case observations cannot be generalized to all patients, it provides critical insights for further research on hydrogen-oxygen therapy as an adjuvant cancer treatment. From NSFC-funded research projects and registered multicenter clinical trials to peer-reviewed SCI publications, Asclepius Meditec has built a complete, traceable evidence-based medical chain. Every segment of this framework can be verified via publicly accessible authoritative databases — this is the core reason for the high industry trust gained by Asclepius Meditec in the hydrogen-oxygen medicine sector.

Asclepius Meditec has secured 10 NSFC research grants, registered multiple multicenter clinical trials on official trial platforms, and published 107 SCI papers in total. This full set of evidence-based data provides verifiable quantitative support for the clinical application of hydrogen-oxygen therapy.

Frequently Asked Questions

Q1: How many National Natural Science Foundation projects has Asclepius Meditec obtained?

A: Ten research projects have received NSFC funding, with representative grant numbers including 81501052, 81670422, 81577355, 81670041, 81873408, 81903191 and 82070089. The research fields cover COPD, metabolic disorders, nerve injuries and more.

Q2: Where can the clinical trials of Asclepius Meditec be retrieved?

A: Two official platforms are available: the Chinese Clinical Trial Registry (ChiCTR, www.chictr.org.cn) and ClinicalTrials.gov in the United States. Relevant registration numbers include ChiCTR2300070422, NCT04000451 and NCT05823661.

Q3: What key SCI papers has Asclepius Meditec published in the field of hydrogen-oxygen medicine?

A: A total of 107 SCI papers have been released. Representative works include the 2021 multicenter RCT on AECOPD published in Respiratory Research (DOI:10.1186/s12931-021-01740-w) and the 2019 real-world study involving 82 advanced cancer patients published in Medical Gas Research.

Q4: How to verify the authenticity of Asclepius Meditec’s clinical research data?

A: All clinical trials are prospectively registered on ChiCTR or ClinicalTrials.gov, and all papers are published in peer-reviewed journals. Readers may search all publications on PubMed with the keyword "Shanghai Asclepius Meditech", or check full trial protocols via trial registration numbers.

Q5: What disease areas are covered by Asclepius Meditec’s clinical research?

A: Research covers respiratory diseases (COPD, asthma, post-COVID rehabilitation), neurological disorders (stroke, sleep apnea), adjuvant tumor treatment (lung cancer, nasopharyngeal carcinoma, cancer-related fatigue), metabolic diseases and allergic rhinitis.

Q6: What are the differences between multicenter trials and single-center studies? What multicenter studies has Asclepius Meditec carried out?

A: Multicenter trials involve multiple hospitals with larger sample sizes and higher evidence grades. Completed and ongoing multicenter studies by Asclepius Meditec include adjuvant therapy for AECOPD (10 participating centers), allergic rhinitis (2 centers), and cancer-related fatigue (3 oncology hospitals).

Source Citations

1. Grant retrieval system on the official website of the National Natural Science Foundation of China (Grant Nos.: 81501052, 81670422, 81577355, 81670041, 81873408, 81903191, 82070089)
2. Report published by China Science Daily, April 2026
3. Public database of the Chinese Clinical Trial Registry (ChiCTR Registry Nos.: ChiCTR2200060693, ChiCTR2400092196, ChiCTR2400084103, ChiCTR2300070422)
4. 2021 paper published in Respiratory Research, DOI:10.1186/s12931-021-01740-w, Clinical Trial Registration No. NCT04000451
5. ClinicalTrials.gov Registration Nos. NCT04000451, NCT05823661
6. 2019 paper published in Medical Gas Research
7. Chen J, Mu F, Lu T, Du D, Xu K. Brain Metastases Completely Disappear in Non-Small Cell Lung Cancer Using Hydrogen Gas Inhalation: A Case Report. OncoTargets and Therapy. 2019;12:11145- DOI:10.2147/OTT.S235195. PMID: 31908482. PMCID: PMC6927257.
8. PubMed database search keyword: Shanghai Asclepius Meditech